viewEnzo Biochem, Inc.

Enzo Biochem shares advance after activist investor ups stake and pushes for takeover, per Seeking Alpha

Roumell Asset Management has raised its stake in the biotech company to 4%

empty board room
'The time has come for the Board to recognize that Enzo Biochem is too small to be successful on its own,' says Roumell

Shares of Enzo Biochem (NYSE:ENZ) pushed higher Wednesday in the wake of a Seeking Alpha report that its activist shareholder Roumell Asset Management has raised its stake in the biotech company to 4% and is demanding a review of its strategic options.

In response to the news, investors sent Enzo shares up 5.6% to $2.70 in afternoon trade.

READ: Enzo Biochem reports a wider-than-expected earnings loss due to decrease in service revenues

As of the close of last year, Roumell had a stake of about 2.3% in the company, according to Seeking Alpha.

In a letter to Enzo’s board, Roumell took the company to task for its share price decline since the start of last year and pushed for its acquisition. “The stock price has declined by nearly 70% since the beginning of 2018. In fact, Enzo’s stock trades below where it traded 20 years ago,” Roumell wrote, according to Seeking Alpha.

“We believe the time has come for the Board to recognize that the company is too small to be successful on its own. We believe it’s likely that the company’s enviable product and IP portfolio would be better suited in a larger company’s hands, where Enzo’s promising AmpiProbe platform can go to market more efficiently and quickly,” Roumell added.

Jim Roumell of Roumell Asset Asset Management was not immediately available for comment. An Enzo representative, meanwhile, declined to comment. 

Contact Ellen Kelleher at [email protected] --

Quick facts: Enzo Biochem, Inc.

Price: 2.53 USD

Market: NYSE
Market Cap: $120.32 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: CytoDyn Get US FDA approval to move to FastTrack to Phase 2...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to discuss the company getting U.S. FDA  clearance to start a Phase 2 trial with leronlimab to treat COVID-19 patients with mild to moderate indications.  Pourhassan telling Proactive why they have been...

16 hours, 26 minutes ago

2 min read